Camber Pharmaceuticals is pleased to announce that it has launched 

 to their current portfolio, which is the generic version of Prevacid®

Lansoprazole DR Capsules are used to treat acid-related throat problems (erosive esophagitis).

Lansoprazole DR Capsules from Camber are available in 15 mg and 30 mg strengths. The 15 mg strength is available in 30, 90 and 500 count bottles. The 30 mg strength is available in 90 and 500 count bottles.

Camber Pharmaceuticals is a fully integrated international pharmaceutical company that maintains quality and integrity in all its products. Its parent company, Hetero Drugs of Hyderabad India, is one of the world’s leading API and finished dosage manufacturers. Camber’s commitment to the consumer is to bring the highest quality generic pharmaceuticals to the market to improve quality of life through cost-effective medications.

Articles

Camber Pharma Launches Generic Prevacid

Upsher-Smith Laboratories, LLC is a company well-known for taking pride in its commitment to product and supply excellence, and today it received some industry validation of its dedicated efforts by receiving a DIANA Award during this year’s Healthcare Distribution Alliance (HDA) virtual Business and Leadership Conference. The DIANA is one of the pharmaceutical distribution industry’s most prestigious awards.

The Maple Grove, Minn.-based pharmaceutical company was honored with the HDA 2021 DIANA Award for the Best Overall Branded Pharmaceutical Product Manufacturer With Less Than $300 Million in Sales to Healthcare Distributors. Each year, HDA distributor members are asked to nominate their top five manufacturer partners and the award is given out based on that process. Upsher-Smith has earned 12 DIANA awards throughout its history, and the award itself has been around since 1959.

“Winning the DIANA for the Branded Rx area says so much about how our wholesaler partners see Upsher-Smith,” says Mike McBride, VP Partner Relations with Upsher-Smith. “As a company, we seek to consistently provide exemplary product quality and supply across both our brand and generic product lines, and we’re proud of our continuing history of product and supply excellence, especially during the unprecedented circumstances of 2020.”

Because of the pandemic, this year’s award ceremony took place online and the Upsher-Smith team participated in a virtual photoshoot to mark the occasion.

Upsher-Smith Laboratories Receives DIANA Award

The faculty at Purdue University doesn’t just talk the talk to promote community pharmacy, they also walk the walk. They have committed to community pharmacy practice transformation by sponsoring Team Indiana through the Flip the Pharmacy initiative. Their investment provides direct coaching to twelve of the nineteen participating pharmacies across the state and advanced community pharmacy practice training for their students through a designated Flip the Pharmacy APPE rotation.

Purdue University College of Pharmacy leaders are passionate about providing their students with the best opportunities to prepare them for their careers. They also recognize that over half of their graduates will work in community practice. With their students’ success in mind, it was an easy decision for Purdue University to become a team sponsor for Team Indiana.

 is a 5-year pharmacy transformation program aiming to re-work community-based pharmacy practice beyond filling prescriptions and toward an ongoing focus on a patient's health.

Margie Snyder, PharmD, MPH, Associate Professor of Pharmacy Practice and Network Director of Rx-SafeNet at Purdue University College of Pharmacy, says that Purdue University is focused on the future of community pharmacy through working with 

ACT (Academia-CPESN Transformation) Pharmacy Collaborative

, Flip the Pharmacy and leading research via 

the Medication Safety Research Network of Indiana (Rx-SafeNet)

, a state-wide community pharmacy practice-based research network.

Snyder is one of three faculty members who works with a postdoctoral research fellow on the “Team Purdue,” the University’s name for its Flip the Pharmacy coaching team directly supporting the 12 aforementioned pharmacies. She explained how their unique program focuses on training fourth year pharmacy students to take the lead as the Practice Transformation Coaches every month, mentored by the faculty coaches.

Using monthly change packages, Flip the Pharmacy coaches work with local pharmacy teams to implement the six key transformation domains with an emphasis on continuing patient care planning with documentation in various eCare plan platforms.

Snyder explained, “On Team Purdue, we have a rotating system among our faculty-preceptors that centers around our APPE students and the pharmacies that they coach in Flip the Pharmacy. Each month, new fourth-year students take over the coaching role with one of the four lead coaches. The transitions are seamless as we require incoming and outgoing students to meet prior to beginning the rotation for a warm handoff that includes an introduction to Flip the Pharmacy, the pharmacies that we serve, and any concerns that need to be addressed in the next month.”

To ensure that the coach is giving each pharmacy the answers and support they need, the students maintain a continuity document. This file addresses all the questions and concerns that the pharmacies bring up during their site visits. Snyder affirmed, “This advanced pharmacy practice experience really works because of our continuity document. It helps us to stay on top of issues just like a single coach would if they visited the same pharmacy month after month.”

Purdue University College of Pharmacy has set up a creative solution to assure practice transformation in Indiana. As a university, they have a focus on transformational leadership by training their students to carry out the vision for the future of community pharmacy. Snyder said, “My vision is that we would be seen as the ‘primary care pharmacists,’ meaning that patients would consistently think of their pharmacist as the medication expert who collaborates directly with their primary care provider.” 

She continued, “Patients would have a full understanding of what we can do to help them, and payers would be willing to compensate us for the clinical interventions that we make on a regular basis.” This is aligned with the vision for Purdue University College of Pharmacy to transform the practice and science of pharmacy to lead advances in human health.

 is a public land-grant research university located in West Lafayette, Indiana. In 2020, they admitted 148 students into the Doctor of Pharmacy program.

The Flip the Pharmacy program hopes to directly support 1,000 pharmacies and impact thousands more. To date, over 800 pharmacies are receiving direct coaching and implementation support. Learn more at 

As one of the first colleges of pharmacy to sponsor a Flip the Pharmacy team, Purdue University commits to the transformation of community pharmacy practice in the state of Indiana. 

Purdue University Invests in the Future of Community Pharmacy

, which is the generic version of Toprol XL®

Metoprolol Succinate ER Tablets is a beta-blocker used to treat chest pain (angina), heart failure, and high blood pressure.

Metoprolol Succinate ER Tablets are available from Camber in 25, 50, and 100 mg in 100, 500 and 1000ct bottles. As well as 200 mg in 100 and 500ct bottles.

Camber Pharma Launches Generic Toprol XL

U.S. News & World Report, the global authority in rankings and consumer advice, and 

®, the leading multimedia resource for pharmacy professionals, today released the

 top-recommended health products for 2021.

 Tylenol came in as the No. 1 pick among the surveyed pharmacists for treating headaches, and Claritin products topped the list for allergy relief in adults and children.

®, provides recommendations from pharmacists for more than 1,000 over-the-counter (OTC) brands across 152 product categories, 133 of which U.S. News also publishes. These results give pharmacists, patients and other health care professionals a trusted resource to promote wellness, prevent and treat acute ailments and illnesses and manage more complex conditions, leading to improved patient outcomes.

Pharmacies are not only accessible and conveniently located, but also are a trusted resource for patients suffering from both common and comorbid conditions. By providing critical services such as patient education, medication dispensing, vaccinations, recommendations for OTC medications and medication management, pharmacy teams continue to be essential. According to the 

Centers for Disease Control and Prevention

, more than 90% of Americans live within five miles of a pharmacy, and patients visit their community pharmacy an average of 12 times more per year than their primary care physician.

As preventive care remains a high priority and COVID-19 vaccinations and CDC guidelines allow more Americans to begin traveling again, the top products can help consumers and their families stay healthy all year long. The No. 1 pharmacist-recommended brands include:

To keep children healthy year-round, the 2021 top-recommended health products for common ailments such as allergies, sore throat and cough include:

This year's picks feature at-home testing products, including Braun ThermoScan 

"As more Americans roll up their sleeves to receive the COVID-19 vaccine, and people begin to travel and return to the office, they're looking for easily accessible information about over-the-counter allergy, headache and pain medicine," said Kim Castro, editor and chief content officer at U.S. News. "The expertise of 

 combined with the in-depth journalism and analysis from U.S. News empowers consumers to research products for their affliction and, along with input from a physician or general practitioner, know that they made the most informed decision for their health."

Ed Cohen, Pharm.D., FAPhA, executive vice president of pharmacy advocacy for 

® gives consumers everywhere insight into which over-the-counter products pharmacists know and recommend. Patients continue to turn to OTC products to treat their conditions and pharmacists continue to counsel and recommend appropriate OTC products. We are proud to be working with U.S. News once again to put together this comprehensive guide of pharmacist recommendations, and we are thankful for the time and effort pharmacists put into taking the survey, especially this year balancing their time with COVID-19 priorities."

 began collaborating in 2012 to bring pharmacist recommendations to consumers nationwide. 

 evaluates pharmacists' insights and preferences through an annual research program conducted by 

HRA® – Healthcare Research and Analytics

, a consultative health care market research practice. Through U.S. News'

, consumers have an easy and searchable way to access the information produced by pharmacists' recommendations. U.S. News displays brands that received at least 1% of pharmacists' votes but awards a No. 1 Pharmacist Recommended Brand designation only to the top-ranked product in each category.

 to access the rankings and search pharmacist recommendations by symptom, product or category.


U.S. News & World Report is the global leader in quality rankings that empower citizens, consumers, business leaders and policy officials to make better, more informed decisions about important issues affecting their lives. A multifaceted digital media company with Education, Health, Money, Travel, Cars, News and 360 Reviews platforms, U.S. News provides rankings, independent reporting, data journalism, consumer advice and U.S. News Live events. More than 40 million people visit USNews.com each month for research and guidance. Founded in 1933, U.S. News is headquartered in Washington, D.C.

® is the industry-leading multimedia pharmacy network of community, health system, oncology, and specialty pharmacy platforms, providing practical clinical and professional information pharmacists can use in their everyday practices when counseling patients and interacting with other health care providers. Each issue and the website contain articles and features covering industry trends, drug interactions, patient education, disease state management, patient counseling, product news, pharmacy law, and more. Additionally, 

™ is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 

™, the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels.

Pharmacists' No. 1 picks include Children's Claritin and Tylenol.

U.S. News & World Report and Pharmacy Times® Reveal 2021 Top-Recommended Health Products

Camber Pharmaceuticals is pleased to announce that it has launched Lopinavir and RitonavirTablets, which is the generic version of Kaletra®

 are used with other HIV medications to help control HIV infection.

Lopinavir and Ritonavir Tablets are available from Camber in 100 mg/25 mg- 60 count and 200 mg/50 mg- 120 count bottles.

Lopinavir and Ritonavir Tablets are used with other HIV medications to help control HIV infection.

Camber Pharma Launches Generic Kaletra

Results from the first phase of the broad, collaborative 

 research study in metastatic non-small cell lung cancer (mNSCLC) were released by 

2021 American Society of Clinical Oncology (ASCO) Annual Meeting

The findings provide a close-up look at current biomarker testing rates and turnaround times for patients with mNSCLC treated in community practices within The Network. Most notably, Protocol 1 findings show that there are barriers that must be addressed as more than 80 percent of NSCLC is detected at Stage 4 and median time from diagnosis to first-line therapy is about five weeks.

“The pace and development of treatments in non-small cell lung cancer is dramatic,” said 

, principal investigator for the MYLUNG Consortium’s Protocol 2 and oncologist with New York Oncology Hematology (

), a practice in The Network. “There are already several targeted therapies to treat subsets of populations, and many more are in the pipeline that hold incredible potential. Unfortunately, barriers exist that prevent the necessary comprehensive biomarker testing that enables the use of these treatments. The MYLUNG Consortium study will be invaluable in identifying these obstacles and developing practical interventions that will allow us to fulfill the promise of precision medicine for patients with this difficult cancer.”

Dr. Evangelist presented the findings during an oral presentation at ASCO titled, “Biomarker tissue journey among patients with untreated metastatic non-small cell lung cancer (mNSCLC) in The US Oncology Network community practices.” (

The MYLUNG Consortium is a collaborative and innovative research study comprised of three protocols over a five-year period. Protocol 1, which was just completed, is a retrospective study of more than 3,500 patients with mNSCLC that investigated the following areas: testing rates for ALK, BRAF, EGFR, ROS1, and PD-L1 mutations; use of the full next-generation sequencing panel (NGS); time from NSCLC diagnosis to first-line therapy; turnaround times from biomarker orders to results; and time from NSCLC diagnosis to test results.

“We have derived significant insights from the study data so far,” noted Sarah Alwardt, PhD, vice president of Operations for Ontada. “We are now able to see where there are gaps regarding targeted therapy. This real-world study showed that while most patients had at least one biomarker test result available prior to first-line therapy, less than 50 percent had five or more biomarkers tested. Consequently, a large percentage of patients were not given the opportunity for a targeted therapy.”

Additionally, the median time from diagnosis to first-line therapy was about five weeks, a concern for patients anxiously waiting for treatment. Turnaround time from testing orders to results was about two weeks, indicating the need to get test results to physicians sooner so they have all critical information in front of them during development of the treatment plan. Next Generation Sequencing testing improved over time, suggesting comprehensive testing is increasing. Most of the population was diagnosed at advanced disease, with roughly over 80 percent detected at stage 4.

“Protocol 1 provides a look at what was happening retrospectively based on clinical data abstraction, allowing us to draw some early conclusions about historical baseline trends for testing patterns,” noted Robert L. Coleman, MD, FACOG, FACS, chief scientific officer of US Oncology Research and the MYLUNG Consortium program principal investigator. “Retrospective studies like this help us understand where we are as far as testing behaviors, while also identifying gaps in the data that need to be filled with the prospective research the MYLUNG Consortium will address in the next protocols.”

Data from Protocol 1 will be compared to the next phase of the MYLUNG Consortium study, Protocol 2, which will evaluate contemporary ordering practices and turnaround times prospectively. It will enroll about 1,000 patients from approximately 11 sites and will monitor the real-world patient journey from presentation through their first line of cancer therapy, focusing on how diagnostic biomarker information is obtained, utilized and operationalized in decision-making. Patients are currently being enrolled in this stage of the study.

The final phase of the study, Protocol 3, will serve as a platform upon which prospectively assessed interventional strategies in patient-engagement algorithms will be conducted. Up to 7,500 patients from approximately 20 participating sites will be recruited over a five-year period. Individual clinical trials will integrate findings from the previous protocols and explore new processes and associated outcomes. The goal is to help providers make the best treatment recommendations based on the data available while improving access to testing and appropriate therapies for patients with mNSCLC.

The MYLUNG Consortium study is enabled through a unique collaboration of various organizations and stakeholders working together across the spectrum of NSCLC drug development, therapy and care. The number of consortium participants continues to grow, all bringing unique perspectives to this innovative study. It brings together providers and researchers in The Network, US Oncology Research and Ontada with life sciences companies 

 are also participating, playing a key role in the study by keeping the focus on patients. Healthcare provider members include 

Willamette Valley Cancer Institute and Research Center

. To schedule a media interview with one of the study investigators, contact Claire Crye at 

 (The Network) helps approximately 1,400 independent physicians deliver value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network provides practices with access to coordinated resources, best business practices, and the experience, infrastructure and support of 

. This collaboration allows the providers in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. The Network is committed to the success of independent practices, everywhere.

Over 80% of non-small cell lung cancer detected at stage 4.

First Phase Results of MYLUNG Consortium Provide Historical View of Biomarker Testing Patterns and Identify Data Gaps for Ongoing Prospective Research

 announce they contributed to more than 75 studies covering topics including gynecologic cancer, lung cancer and immunotherapy which will be presented at the upcoming 2021 American Society of Clinical Oncology (

) Annual Meeting, to be held virtually from June 4 - 8.

“At this year’s ASCO Annual Meeting, we are looking forward to sharing our latest insights and knowledge across the global oncology community,” said Robert L. Coleman, MD, chief scientific officer, US Oncology Research. “As we emerge from a year that challenged how we approach the fight against cancer, it is more important than ever to discuss how we can work together to ensure this next chapter of commitment to equitable care and innovation.”

Key highlights include a plenary session exploring the role of adjuvant chemotherapy following chemoradiation in women with cervical cancer, featuring results from OUTBACK, a randomized Phase III trial to determine if the addition of adjuvant chemotherapy to standard cisplatin-based chemoradiation improves rates of overall survival. The plenary session, which will be held Sunday, June 6 from 1 -4 p.m. ET, will feature abstract LBA3, “Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial.”

“Despite the recently developed cervical cancer vaccine, many women will continue to die from this disease if existing treatments are not improved,” said 

, co-author of the study and oncologist with 

, a practice in The Network. “We are eager to present the results from this featured late-breaking plenary and to draw attention to the problem of cervical cancer among women in developing nations.”

Also of note this year are findings from the 

 study, which will be featured in an oral abstract session. Given the importance of molecular testing and targeted therapy for metastatic non-small cell lung cancer, the findings provide an assessment of real-world biomarker testing rates and turnaround times of more than 1,000 providers across the U.S. The session titled, “Lung Cancer—Non-Small Cell Metastatic,” will be held Friday, June 4 from 1 – 4 p.m. ET and will feature abstract 9004, “

Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in The US Oncology Network community practices

“While treatment decisions based on molecular analyses can improve outcomes, many patients do not undergo timely comprehensive testing,” said 

, study co-author, principal investigator for Protocol 2 of the MYLUNG Consortium and oncologist with New York Oncology Hematology (

), a practice in The Network. “Through this real-world analysis, we observed that less than half of patients with mNSCLC had five or more biomarkers tested before initiating first-line systemic therapy. These findings deepen our understanding of the barriers patients face and help us target new approaches for improving their care.”

“Through the MYLUNG Consortium, we are able to bring together providers, life sciences companies and patient advocacy groups with a common goal of improving patient outcomes,” added Dr. Coleman, who is the MYLUNG Consortium program principal investigator. “What we are presenting at this year’s ASCO Annual Meeting are findings from Protocol 1. This innovative study will last five years with about 20 participating sites recruiting up to 12,000 patients.”

In a poster session, results will be presented from a retrospective study leveraging electronic health record data from the Ontada database of adult patients with extensive-stage small cell lung cancer (ES-SCLC). The study investigated patient characteristics and treatment patterns for patients with ES-SCLC receiving treatment in the real-world community setting. The session titled, “Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,” will be held Sunday, June 6 from 8 – 11 a.m. ET and will feature abstract 8561, “

Real-world evidence of cancer immunotherapy (CIT) combination treatment in first line (1L) extensive-stage small cell lung cancer (ES-SCLC)

“This study was the first real-world study that analyzed the incorporation of immunotherapy in the treatment of small cell lung cancer,” said 

, a practice in The Network. “Being able to leverage real-world data into today’s clinical research is a huge step forward. We now have the ability to take a plethora of already available and extremely valuable data and study thousands of patient journeys for numerous indications.”

Ontada President Susan Shiff, PhD, MBA, concludes, “We are excited to present the results of studies that have used a variety of retrospective and prospective methodologies whose findings can help to improve the lives of cancer patients, which of course is our ultimate goal.”

You can find the full schedule of affiliated data presentations from US Oncology Research, The US Oncology Network and Ontada at ASCO this year, including author details, 

. For more information or to interview a trial investigator, contact Claire Crye at 281.825.9927 or 

 draws from a network of experienced investigators and dedicated clinical staff who specialize in oncology clinical trials. US Oncology Research serves approximately 60 research sites and more than 165 locations, managing about 400 active trials at any given time. For the past 20 years, physicians in the research network have enrolled more than 85,000 patients in over 1,600 trials and have played a role in more than 100 FDA-approved cancer therapies. US Oncology Research is supported by 

 is an oncology data, research and technology business dedicated to improving the lives of cancer patients. Part of 

, we partner with life sciences companies to support science through real-world data and evidence, helping to accelerate drug development and commercialization, connect community oncology providers to educational programs that enable them to practice at the forefront of therapies, and advance precise, evidence-driven patient care through practice technologies in the community setting. For more information, visit 

Key highlights include a plenary session on cervical cancer among women in developing nations and an oral abstract exploring molecular testing and targeted therapy for metastatic non-small cell lung cancer, among other topics.

US Oncology Research, The US Oncology Network and Ontada Announce Clinical Data Showcased in Plenary and Oral Sessions at ASCO Annual Meeting

Videos

Infusing Hizentra With Prefilled Syringes

WARNING: Thrombosis (blood clots) can occur with immune globulin products, including Hizentra. Risk factors can include: advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (blood thickness), use of estrogens, installed vascular catheters, and cardiovascular risk factors.

If you are at high risk of blood clots, your doctor will prescribe Hizentra at the minimum dose and infusion rate practicable and will monitor for signs of clotting events and hyperviscosity. Always drink sufficient fluids before infusing Hizentra.

See your doctor for a full explanation, and the full prescribing information for complete boxed warning.

Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, is a prescription medicine used to treat:

Primary immune deficiency (PI) in patients 2 years and older

Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults

Treatment with Hizentra might not be possible if your doctor determines you have hyperprolinemia (too much proline in the blood), or are IgA-deficient with antibodies to IgA and a history of hypersensitivity. Tell your doctor if you have previously had a severe allergic reaction (including anaphylaxis) to the administration of human immune globulin. Tell your doctor right away or go to the emergency room if you have hives, trouble breathing, wheezing, dizziness, or fainting. These could be signs of a bad allergic reaction.

Inform your doctor of any medications you are taking, as well as any medical conditions you may have had, especially if you have a history of diseases related to the heart or blood vessels, or have been immobile for some time. Inform your physician if you are pregnant or nursing, or plan to become pregnant.

 Self-administer Hizentra only after having been taught to do so by your doctor or other healthcare professional, and having received dosing instructions for treating your condition.

Immediately report to your physician any of the following symptoms, which could be signs of serious adverse reactions to Hizentra:

Reduced urination, sudden weight gain, or swelling in your legs (possible signs of a kidney problem).

Pain and/or swelling or discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid pulse, or numbness/weakness on one side of the body (possible signs of a blood clot).

Bad headache with nausea; vomiting; stiff neck; fever; and sensitivity to light (possible signs of meningitis).

Brown or red urine; rapid heart rate; yellowing of the skin or eyes; chest pains or breathing trouble; fever over 100°F (possible symptoms of other conditions that require prompt treatment).

Hizentra is made from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.

The most common side effects in the clinical trials for Hizentra include redness, swelling, itching, and/or bruising at the infusion site; headache; chest, joint or back pain; diarrhea; tiredness; cough; rash; itching; fever, nausea, and vomiting. These are not the only side effects possible. Tell your doctor about any side effect that bothers you or does not go away.

Before receiving any vaccine, tell immunizing physician if you have had recent therapy with Hizentra, as effectiveness of the vaccine could be compromised.

 for Hizentra, including boxed warning and the 

Treatment with Hizentra might not be possible if your doctor determines you have hyperprolinemia (too much proline in the blood), or are IgA-deficient with antibodies to IgA and a history of hypersensitivity. 

Press Releases